Recent blog posts
Advancements in Clinical Research and Development of Obesity Treatment Medications
Hot Spotlight
21 min read
Advancements in Clinical Research and Development of Obesity Treatment Medications
7 March 2024
In February, University of Leicester and Leicester Diabetes Centre experts published a summary of obesity treatments in "International Journal of Obesity," highlighting new drugs inspired by gut incretin hormones.
Read →
Progress in the Discovery of New Drugs Targeting GPCR Class for Gastric Cancer
Hot Spotlight
14 min read
Progress in the Discovery of New Drugs Targeting GPCR Class for Gastric Cancer
1 March 2024
Gastric Cancer (GC) is a deadly global malignancy with over 1 million new cases in 2022, resulting in 783,000 deaths.
Read →
Development Trends of Peptide Pharmaceuticals
Hot Spotlight
17 min read
Development Trends of Peptide Pharmaceuticals
1 March 2024
This article provides an interpretation of a review published in the 2021 issue of "Nature Reviews Drug Discovery", which analyzes the history and trends of peptide drug development over the past 100 years.
Read →
Clinical Dose and Translational Science of the JAK1 Inhibitor Upadacitinib
Hot Spotlight
11 min read
Clinical Dose and Translational Science of the JAK1 Inhibitor Upadacitinib
27 February 2024
Upadacitinib acts as an ATP-competitive JAK inhibitor; it competes with ATP and blocks nucleotide binding to inhibit kinase activity and the phosphorylation of downstream effectors.
Read →
Progress in the Research and Development of Cannabinoid Receptor New Drugs
Hot Spotlight
12 min read
Progress in the Research and Development of Cannabinoid Receptor New Drugs
27 December 2023
Cannabinoids can be categorized into three types based on their origin: endocannabinoids, phytocannabinoids, and synthetic cannabinoids.
Read →
ADC drugs worth paying attention to in Clinical Phase III/II/I
Hot Spotlight
10 min read
ADC drugs worth paying attention to in Clinical Phase III/II/I
17 November 2023
Apart from the approved ADCs, there are hundreds of ADCs under clinical investigation, covering a increasingly diverse range of targets.
Read →
Sale of GLP-1 Small Molecule to Eli Lilly, Chugai Pharmaceutical Discloses Latest KRAS Macrocyclic Patent
Hot Spotlight
7 min read
Sale of GLP-1 Small Molecule to Eli Lilly, Chugai Pharmaceutical Discloses Latest KRAS Macrocyclic Patent
16 November 2023
Last year belonged to the realm of Pfizer's COVID-19 small molecule treatments, while this year is dominated by GLP-1 injectable and oral therapies.
Read →
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
Hot Spotlight
6 min read
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
8 November 2023
In late October, Hengrui and Merck agreed on a €1.4 billion transaction, with a first payment of €160 million. The deal mainly involves Hengrui's self-developed PARP1 inhibitor HRS-1167 and Claudin-18.2 ADC SHR-A1904.
Read →
Merck reports the use of LRRK2 inhibitor for Parkinson's treatment
Hot Spotlight
7 min read
Merck reports the use of LRRK2 inhibitor for Parkinson's treatment
26 October 2023
Merck Company published an article in the Journal of Medicinal Chemistry (JMC) on the 20th of this month, reporting on the discovery process of LRRK2 inhibitor MK1468.
Read →
The GLP-1R plus strategy for curbing the obesity epidemic
Hot Spotlight
5 min read
The GLP-1R plus strategy for curbing the obesity epidemic
14 July 2023
this approach brings new hope that we can finally address the growing concern of obesity worldwide.
Read →
AXS-05 or Ketamine,Which is a better choice for depression?
Hot Spotlight
10 min read
AXS-05 or Ketamine,Which is a better choice for depression?
10 July 2023
For most patients with severe depression, monoamine-targeted first or second-line treatments often cannot achieve sufficient therapeutic effects.
Read →